Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454941 | 0.86 | NPC1 (0.47) | NPC1KMT2AABCB1ABCC1PTGDR2 | |
| SCHEMBL5452220 | 0.85 | NPC1 (0.44) | NPC1KMT2AABCB1ABCC1PTGDR2 | |
| SCHEMBL5465878 | 0.83 | MAPT (0.45) | NPC1KMT2AABCB1ABCC1PTGDR2 | |
| SCHEMBL5446440 | 0.83 | HTR6 (0.43) | NPC1KMT2AABCB1ABCC1PTGDR2 | |
| SCHEMBL5454152 | 0.82 | MAPT (0.47) | NPC1KMT2AABCB1ABCC1PTGDR2 | |
| SCHEMBL5457361 | 0.82 | PTGDR2 (0.53) | ABCB1ABCC1PTGDR2 | |
| SCHEMBL5466142 | 0.80 | PTGDR2 (0.46) | PTGDR2 | |
| SCHEMBL5455286 | 0.79 | PTGDR2 (0.40) | NPC1KMT2AABCB1ABCC1PTGDR2 | |
| SCHEMBL5449739 | 0.79 | NPC1 (0.45) | NPC1KMT2APTGDR2 | |
| SCHEMBL5455136 | 0.74 | NPC1 (0.49) | NPC1KMT2AABCB1ABCC1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | HDAC1 676/4885HDAC6 978/4885NPC1 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.